RxDoctor Payments Data

Raymond Perkins, MD

Pulmonary Disease · Round Rock, TXNPI 1548268501

Payments from drug & device makers

$99,348in general payments, 2019–2025

Across 312 payments — averaging $318.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$69K
  • Boehringer Ingelheim$23K
  • AstraZeneca$5K
  • United Therapeutics Corporation$425
  • Electromed, Inc.$291
  • Regeneron Healthcare Solutions, Inc.$194
  • plus $1K from 19 others

What the payments were for

  • Consulting fees$2340%
  • Speaking & faculty fees$92,30093%
  • Travel & lodging$9921%
  • Food & beverage$5,7656%
  • Education$570%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$99,348 in reported general payments places this provider in the 85th percentile of 904 pulmonary disease providers in Texas.

See all pulmonary disease providers in Texas

Medicare billing

Part B allowed, 2024
$62,701
Medicare patients
559
Services billed
1,096

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate29$502,077
Trelegy ElliptaFluticasone/Umeclidin/Vilanter368$281,704
Stiolto RespimatTiotropium Br/Olodaterol Hcl127$72,518
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr120$71,819
Breztri AerosphereBudesonide/Glycopyr/Formoterol76$56,054
Breo ElliptaFluticasone/Vilanterol35$18,730
Fluticasone-SalmeterolFluticasone Propion/Salmeterol74$12,101
Azithromycin369$8,438
Albuterol Sulfate HfaAlbuterol Sulfate206$7,713
Combivent RespimatIpratropium/Albuterol Sulfate12$6,538
Wixela InhubFluticasone Propion/Salmeterol38$5,155
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate19$4,674
Ipratropium Bromide161$4,382
Roflumilast15$3,824
Ventolin HfaAlbuterol Sulfate37$2,068

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Stiolto Respimat, Combivent Respimat$23,023$581,132168 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$69,368$372,253523 claims
AstraZenecaBreztri Aerosphere$4,778$56,05476 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 904 pulmonary disease providers in Texas.

Other pulmonary disease in Round Rock

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →